One Family Killed an Entire Branch of Medicine. They’re Back.

And this week the FDA quietly ran the same play on peptides. Here's the receipts.

A hundred years ago one family decided what would count as medicine in America, and they erased everything else. They wiped out entire schools with centuries of tradition and thousands of doctors. Most people have never heard about it, and that’s exactly how they wanted it.

I’m going to walk you through how they did it, because once you see the first time, you’ll understand why they’re coming for peptides now. It comes down to one thing. You cannot patent something the body already makes. If they can’t patent it, they can’t own it, and if they can’t own it, they can’t sell it back to you for the rest of your life. That’s the whole fight. Everything else is theater.

What medicine looked like before they got to it

To understand what was taken, you have to see what was there first.

Before 1900 American medicine looked nothing like it does today. There was no FDA, no standardized training, and no pharmaceutical giant deciding what got prescribed. People couldn’t even agree on what medicine was. Different schools ran on completely different philosophies. You had the regular physicians leaning on aggressive interventions like bloodletting and mercury. You had homeopaths working with heavily diluted substances. You had eclectic doctors who blended conventional treatment with botanical remedies, naturopaths who leaned on the body’s own capacity to heal, and dozens of smaller traditions on top of that.

And none of them had a monopoly. Patients chose their doctor based on who actually got them better, not on who had the right credential. If the regular physician’s mercury made you sicker, you walked down the street to the herbalist. If the herbalist couldn’t touch your problem, you tried the homeopath. That competition forced every school to produce real results or lose their patients. It was a market of outcomes, and it kept everyone honest.

And the botanical schools held their own in that market. Places like the Eclectic Medical Institute in Cincinnati and the Physio-Medical College of Indiana were graduating hundreds of doctors a year. These were not fringe operations. They had decades of history and real training programs, and their patient outcomes stood next to conventional medicine and often beat it.

That shouldn’t surprise anyone, because plant medicine had been the foundation of healing for thousands of years, and a lot of it flat out worked. Willow bark for pain gave us the compound that became aspirin. Foxglove for the heart gave us digitalis. Cinchona bark for malaria gave us quinine. These weren’t superstitions. They were working medicines backed by generations of documented use.

But botanical medicine had one fatal flaw, and it had nothing to do with whether it worked. You cannot patent a plant. Anyone with a backyard could grow willow bark or harvest foxglove, and there’s no way to build a monopoly on knowledge that has been public for centuries.

John D. Rockefeller understood that better than anyone alive.

How one family rewrote the rules

In 1910 America had 165 medical schools. By 1925 only 81 were left, and not one of them taught herbal medicine anymore.

Fifteen years. That’s all it took to wipe out an entire branch of medicine. It didn’t happen because the science suddenly proved plants don’t work. It happened because of money, and one family in particular.

Rockefeller had already become the richest man in America through Standard Oil, and he’d perfected one playbook to get there. Undercut your competition until they go broke, buy up what’s left for pennies, then control the whole supply chain so customers have nowhere else to go. He wanted to run that same play on medicine. The trouble was that medicine wasn’t like oil. You couldn’t drill for it and own the wells. It was spread across hundreds of schools and thousands of practitioners, with families passing remedies down through the generations.

So he didn’t go after the medicine. He went after the people who got to decide what counted as medicine.

In 1901 he founded the Rockefeller Institute for Medical Research. The public story was philanthropy, a rich man giving back by funding science. The private reality was the opening move in a takeover. The institute didn’t fund just any research. It funded work on synthetic compounds that could be patented, laboratory science that needed equipment only big institutions could afford, and drug development that would build dependence on pharmaceutical companies.

To run it he brought in a former Baptist minister turned business advisor named Frederick Gates. Gates understood that controlling medicine meant controlling the gatekeepers. The schools that trained the doctors. The licensing boards that decided who could practice. The journals that decided what counted as legitimate. The strategy he laid out was simple and ruthless. Use philanthropy to gain influence over medical education. Fund the schools that taught the pharmaceutical model and starve the ones that didn’t. Then build a standardization system that would wipe out the competition while calling it a fight for quality.

There was one thing the plan still needed. Credibility. They couldn’t just announce that herbal schools were inferior. They needed someone respectable to say it for them, someone the establishment would believe.

They found their man in Abraham Flexner.

The report that closed the doors

Abraham Flexner was not a doctor. He’d never practiced medicine and never attended medical school. He ran a private school in Louisville and had written a book criticizing American colleges, and that book is what caught the eye of the Carnegie Foundation, which was already working hand in glove with Rockefeller on the medical education project.

In 1908 they hired him to survey every medical school in America. Carnegie paid for the study and Flexner did the visits and wrote the report, with the Rockefeller Institute standing ready to implement whatever it recommended. On the surface it looked noble. Evaluate the quality of medical education and help raise the standards. But the criteria Flexner used weren’t neutral. They were built to favor one kind of medicine over every other.

His standards demanded expensive laboratory facilities, full-time faculty with research credentials, extensive hospital-based clinical training, standardized curricula modeled on the Europeans, and entrance requirements steep enough to thin the applicant pool. Every one of those made perfect sense for pharmaceutical medicine, which was lab-based, equipment-heavy, and tied to hospitals. Not one of them made sense for botanical medicine, which was practice-based, built on gardens and field knowledge, and had trained effective doctors through apprenticeship for centuries.

The herbal schools couldn’t meet those standards without tearing out everything that made them work. They’d have to rip up the gardens and put in laboratories, fire their experienced practitioners and hire research PhDs, and stop teaching people how to grow their own medicine so they could teach them to prescribe patented drugs instead. It was a setup. The standards weren’t written to measure quality. They were written to eliminate competition.

Flexner spent two years visiting around 155 schools. He gave most of them less than a day, some only a few hours. He didn’t evaluate patient outcomes. He didn’t interview graduates or check long-term success rates. He measured buildings, equipment, and whether the school matched criteria that had already been decided.

The 1910 Flexner Report landed like a bomb. It branded more than half of America’s medical schools inadequate overnight. Herbal, homeopathic, and naturopathic schools that had run successfully for decades were condemned as unscientific and dangerous, and the report recommended most of them be shut down immediately.

Then the money showed up.

Within months, Rockefeller’s General Education Board began handing out grants no school could match, but only to schools that agreed to implement Flexner’s recommendations and restructure around pharmaceutical medicine. The sums were staggering for the time. Washington University in St. Louis took in $75,000 in 1910, worth over two million in today’s dollars. Johns Hopkins got even more. Yale, Harvard, and Columbia all took massive Rockefeller grants, but only after agreeing to drop their homeopathic departments and rebuild around drug-based training.

Refuse the money and you were trapped. The state licensing boards, following the Flexner Report, had started requiring graduates to come from accredited schools, and accreditation required meeting Flexner’s standards, which required money most schools didn’t have. It was a trap with one exit, and the exit led exactly where they wanted you to go.

The Eclectic Medical Institute in Cincinnati had been training doctors since 1830. Eighty years of graduates had given it a solid reputation built on results that held up. They refused to abandon botanical medicine, so the funding was refused. They couldn’t afford the laboratories Flexner demanded, so they lost accreditation. Once they lost accreditation they couldn’t legally graduate doctors, and by 1939 they were forced to close.

Some schools tried to save themselves by playing along. The New York Homeopathic Medical College built the labs, hired the research faculty, and restructured the curriculum while trying to keep its homeopathic focus. It didn’t matter. Rockefeller’s foundation denied them funding anyway, and by 1918 they’d merged with a conventional school and dropped homeopathy entirely. Hahnemann in Philadelphia, one of the most prestigious homeopathic institutions in the country, held out longer, but without funding its facilities aged while the Rockefeller-backed schools built modern campuses, its faculty left for better pay, and by 1950 homeopathic training there was gone too. That same story repeated across the country until the schools were finished.

They went after the doctors already practicing, too

Closing the schools handled the next generation. But there were still tens of thousands of herbalists, naturopaths, and homeopaths out there with established practices and patients who trusted them. They’d been trained before the report, they had decades of experience, and you couldn’t just shut them down.

So they went after the licensing boards instead. Every state had a board that decided who could legally practice, and before 1910 most of them were fairly open. Graduate from any legitimate school, show you were competent, and you got licensed. Different philosophies coexisted under one roof. The Flexner Report blew that apart by recommending that boards only recognize graduates of accredited schools, and accreditation only went to schools teaching the pharmaceutical model.

Rockefeller’s foundations then funded the campaigns to get state legislatures to adopt the new rules. They wrote model legislation. They paid for the lobbying. In some cases they funded the salaries of the very board members who backed their position. State by state the requirements changed, New York in 1915, California in 1917, Illinois in 1921, until it became effectively illegal to practice botanical medicine even if you’d been doing it successfully for thirty years.

The doctors already practicing got grandfathered in, which sounds generous until you see what it actually did. They could keep working, but they couldn’t train new apprentices and they couldn’t pass the knowledge down. When that generation retired or died, their medicine died with them. No dramatic ban required. Just wait it out and let the clock do the work.

The older physicians fought back. They filed lawsuits arguing the new laws violated their right to practice. They organized associations, lobbied legislatures, and published journals documenting their patient outcomes to prove their methods worked. It didn’t matter, because Rockefeller’s foundations had effectively unlimited money for the fight. They funded counter-lobbying, placed favorable articles in the major papers, and bankrolled universities to produce studies showing pharmaceutical superiority.

The propaganda machine that made it stick

Here’s the part that turned a business takeover into something the public actually cheered for.

None of this happened in the dark. It happened in full view, dressed up as progress. Medical journals that took drug-company advertising ran editorials attacking herbal medicine as primitive and dangerous. Newspapers that lived on pharmaceutical ad money ran stories about quacks and con artists, and they were careful to lump legitimate, experienced herbalists in with actual frauds so the whole field looked like a scam.

The American Medical Association, which had been reorganized with Rockefeller money, ran its own operation. In 1906 it created a propaganda department, later renamed the Bureau of Investigation, and its explicit job was to attack alternative medicine and anyone who practiced it. Its lead investigator spent decades writing exposés of homeopaths, naturopaths, chiropractors, and herbalists, and his work ran in the AMA’s own journal and got reprinted in papers across the country. The message never changed. Pharmaceutical medicine was scientific and trustworthy, and everything else was quackery.

What never got mentioned in any of it was that the AMA was itself taking heavy funding from the drug companies and the Rockefeller foundations. It wasn’t an independent authority. It was a lobbying arm for the industry it claimed to police.

Then came the financial squeeze. The Sheppard-Towner Act of 1921 looked, on its face, like a good and gentle law. It provided federal money for maternal and infant health, prenatal care, the kind of thing almost nobody would argue against. But buried in how it worked was a requirement that the federal money could only go to programs staffed by doctors from accredited schools, meaning schools that taught pharmaceutical medicine and nothing else. Midwives who had safely delivered babies for generations were suddenly ineligible. Naturopaths who specialized in prenatal nutrition were shut out. Families who wanted those practitioners had to pay out of pocket while their own tax dollars subsidized only the pharmaceutical approach.

That’s the real lesson of monopoly power, and they understood it perfectly. You don’t have to make your product better than the competition. You just have to make the competition inaccessible.

By 1925 the transformation was complete. Of the 165 schools operating in 1910, only 81 remained, and every one still teaching primarily botanical medicine had either closed or fully converted to drugs. Knowledge refined over centuries began vanishing, not because it stopped working and not because something better replaced it, but because there was no longer any legal way to teach it, practice it, or get paid for it.

We’re still living in the system they built

The consequences didn’t show up all at once. At first the pharmaceutical model delivered on real promises. Antibiotics saved lives. Surgery fixed things that used to kill people. I’m not going to pretend otherwise, and neither should anyone making this argument honestly.

But the drug model was built for one kind of problem and blind to another. It handled the acute stuff, an infection or an injury or an emergency, the kind of crisis you resolve by hitting it hard and fast. It struggled with the slow, systemic stuff. Chronic conditions, autoimmune disease, metabolic disorders, mental health, the things that build over years and need long-term support rather than one aggressive intervention. Botanical medicine had spent centuries developing exactly that kind of support, and that was the knowledge that got erased.

So look at where it left us. By the 1960s Americans were the most medicated population in human history, with pills for blood pressure, cholesterol, mood, sleep, digestion, and inflammation, many of them for conditions earlier generations had managed with food, herbs, movement, and time. When the only tool a doctor is trained to reach for is a prescription pad, every problem starts to look like a shortage of some patented compound.

The costs tell the same story. In 1960 Americans spent about $27 billion on healthcare, roughly 5 percent of the economy. By 2020 it was around $4 trillion, nearly 20 percent. We now spend more on healthcare than any nation on earth and take more prescription drugs than any population in history, and we are sicker than we’ve ever been. Most American adults take at least one prescription drug, chronic disease affects the majority, and autoimmune and mental health diagnoses keep climbing. Something in the model isn’t working, and it isn’t an accident. It’s the shape of a system built to treat customers, not to cure them.

Why this matters for peptides right now

Here’s where it comes back around to today, and this part is my read on it, not a history lesson.

The same logic that closed those schools is the logic aimed at peptides right now.

Peptides are short chains of amino acids. Your body already makes them. They’re signaling molecules that tell your cells what to do. Think about the ones people are talking about right now, from BPC and TB-500 to the GLP compounds and the bioregulators. These are not foreign chemicals invented in a lab to be patented. Most of them are sequences the body already recognizes because it produces versions of them on its own.

And that’s the problem, from the monopoly’s point of view. You cannot build a hundred year empire on a molecule that anyone can synthesize and that the body makes for free. There’s no moat around it and no exclusive license to sell, which means no reason a patient has to come through their door and theirs alone.

So watch what happens. The same moves are showing up that showed up a century ago. The framing that it’s all unproven and dangerous. The push to make it inaccessible rather than illegal, because inaccessible is quieter and works just as well. The articles that lump careful researchers in with actual bad actors so the whole space looks like a scam. They learned a long time ago that you don’t have to prove your competition is worse. You just have to make it too expensive and too complicated for people to reach.

And if you think I’m talking in the abstract, look at what just landed this week. The FDA’s Pharmacy Compounding Advisory Committee is meeting on July 23 and 24 to decide whether seven peptides get a legal home on something called the 503A Bulks List, which is the line between a licensed pharmacy being able to compound these for patients and the whole thing staying stuck in a gray zone. The seven up for review are BPC-157, KPV, TB-500, MOTS-c, plus Emideltide, Semax, and Epitalon. Ahead of the meeting the agency posts its own briefing documents, and those documents are now public. The position is the same for every single one. No. Free base or acetate, it doesn’t matter, they’re proposing all of them stay off the list, which is fourteen line items when you count both forms of each peptide, and the recommendation on all fourteen is do not include.

Let me be straight about the reasons they gave, because the real version is telling enough without me dressing it up. The documents don’t call peptides poison. They lean on what’s missing instead. No standardized name. No documented history of pharmacy compounding. No human studies proving it works. A safety flag over immunogenicity because nobody has run the human trials to rule it out. For TB-500 they even pointed to a lab study where it failed to close wounds in a dish, and noted that the supporting papers the nominator submitted were actually about a different, larger parent molecule. Now read those reasons back and notice that every one of them comes down to a lack of studies. And who funds the studies that would fill those gaps? Drug companies do, because at the end of that road sits a patent worth twenty years of exclusive sales. Nobody spends tens of millions running human trials on a molecule the body already makes and anyone can synthesize, because there’s no payday waiting at the finish. So the studies never get run, and then the absence of those same studies becomes the official reason the compound can’t have a legal path. You can’t patent it, so nobody funds the trials, so the trials don’t exist, so the agency says there isn’t enough evidence, so it stays locked out. The molecule gets punished for the exact thing that makes it a threat.

There’s a detail almost nobody is reporting, and it stopped me cold when I read it. Every one of these nominations had already been withdrawn. The companies that originally asked for the review pulled their requests, and the FDA decided to proceed anyway. It says so right in the documents, peptide after peptide. Nobody was standing at the front of the line demanding a vote, and the agency pulled these forward on its own to put a no on the record. It’s worth asking who that agency actually answers to, because the public still pictures a taxpayer-funded watchdog and that picture is out of date. Industry user fees, money paid to the FDA by the drug companies it regulates, now cover close to half of its total budget, somewhere around 45 to 49 percent as of 2025. Zoom in on the specific program that reviews prescription drugs and the industry share runs near 77 percent, with taxpayers covering the rest. In 1993 that share was 7 percent. You don’t need a single bribe for that to bend behavior. When the people being judged are also the people funding the building, the tilt is structural, and economists have a name for it. They call it regulatory capture, and it’s a documented failure mode of regulation, not a fringe theory.

None of this flips your access overnight, and I won’t pretend otherwise. It’s a proposal and a recommendation, and any real change still runs through months of formal rulemaking. But the direction is unmistakable. A unanimous no on all seven signals the pharmacies, the payment processors, and the platforms all at once. Access rarely dies from one dramatic ban. It dies from the slow tightening, exactly the way it died the first time.

I’m not telling you to throw out modern medicine. I won’t pretend antibiotics don’t save lives or that emergency medicine isn’t a miracle when you need it. That stuff is real and I’d use it without thinking twice. The drug model does what it was built to do. The point isn’t that drugs are bad. The point is what happens when one approach becomes the only approach anyone is allowed to offer you, not because it won on the merits but because it was the only one somebody could own.

This isn’t ancient history. There are people alive right now whose grandparents trained in schools that no longer exist, who remember when botanical medicine was a normal choice instead of a fringe practice. The knowledge wasn’t lost to time. It was deliberately destroyed within living memory, and we’re still paying for it in a system that’s brilliant at expensive interventions and terrible at keeping people well.

Rockefeller didn’t destroy botanical medicine because it was unscientific. He destroyed it because it was unprofitable. Knowledge that can’t be patented, controlled, and sold at monopoly prices is worthless to someone building an empire, no matter how well it works.

That’s the question worth sitting with. Not whether peptides are perfect. Whether you should be the one deciding what goes in your body, or whether that decision belongs to the people who figured out a long time ago that the money was never in curing you. It was in keeping you a customer.

They did it to the herbalists. They’re trying it again.

Pay attention to who profits from telling you to look away.

Want to go deeper on this? I break it all down inside the Peptides and Biohacking Hub on Skool. It’s a free community where we get into the history, the regulation, the protocols, and everything I can’t fit into one post. If you’ve got questions or you just want to talk this through with people who actually get it, that’s where to find me. Come join us and jump in the thread.

Join here: https://www.skool.com/peptides-biohacking-hub

Stay sharp, Joe Mars The Peptide Report

This is education and my own opinion, not medical advice. Do your own research and work with someone you trust.